BCR-ABL1 translocations (Ph+) are more prevalent in adult vs. pediatric patients diagnosed as Mixed Phenotype Acute Leukemia (MPAL) [12,13]. The BCR-ABL1 translocations are considered to be prognostic of poorer outcomes in the context of patients diagnosed with Mixed Phenotype Acute Leukemia (MPAL) [12]. However, a number of individual studies indicate that Ph+ MPAL patients can be treated successfully wiht tyrosine kinase inhibitors (TKI) such as Imatinab and second generation TKIs (14,15). | BCR-ABL1 translocations (Ph+) are more prevalent in adult vs. pediatric patients diagnosed as Mixed Phenotype Acute Leukemia (MPAL) [12,13]. The BCR-ABL1 translocations are considered to be prognostic of poorer outcomes in the context of patients diagnosed with Mixed Phenotype Acute Leukemia (MPAL) [12]. However, a number of individual studies indicate that Ph+ MPAL patients can be treated successfully wiht tyrosine kinase inhibitors (TKI) such as Imatinab and second generation TKIs (14,15). |